Revenue potential from the AML pathways combined is about AUD $1.5B U(S, Europe, Australia) as it is broad-based application of AML. Add another AUD $10B for the mainstream cancers (Breast & Ovarian).
These are my calculations. The background to them is in other threads.
My view remains ... RAC will be bought out during Phase II clinical trials as that is what usually happens to drug development biotechs. See indicative values in post above.
RAC Research Primer - June 2020, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
-0.015(1.15%) |
Mkt cap ! $213.9M | |||
| Open | High | Low | Value | Volume |
| $1.33 | $1.35 | $1.28 | $34.20K | 26.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 682 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.35 | 1824 | 1 |
View Market Depth
| Last trade - 16.10pm 25/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.31 |
Change
-0.015 ( 0.38 %) |
||||
| Open | High | Low | Volume | ||
| $1.32 | $1.35 | $1.28 | 9710 | ||
| Last updated 15.59pm 25/04/2024 ? | |||||
| RAC (ASX) Chart |